These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893 [TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029 [TBL] [Abstract][Full Text] [Related]
7. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Lai CJ; Monath TP Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441 [TBL] [Abstract][Full Text] [Related]
8. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547 [TBL] [Abstract][Full Text] [Related]
11. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060 [TBL] [Abstract][Full Text] [Related]
12. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637 [TBL] [Abstract][Full Text] [Related]
13. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001 [TBL] [Abstract][Full Text] [Related]
14. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. Monath TP; Arroyo J; Levenbook I; Zhang ZX; Catalan J; Draper K; Guirakhoo F J Virol; 2002 Feb; 76(4):1932-43. PubMed ID: 11799188 [TBL] [Abstract][Full Text] [Related]
15. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. van Der Most RG; Murali-Krishna K; Ahmed R; Strauss JH J Virol; 2000 Sep; 74(17):8094-101. PubMed ID: 10933719 [TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795 [TBL] [Abstract][Full Text] [Related]
17. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism. Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184 [TBL] [Abstract][Full Text] [Related]
18. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643 [TBL] [Abstract][Full Text] [Related]
19. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873 [TBL] [Abstract][Full Text] [Related]
20. [Construction of recombinant yellow fever virus 17D containing 2A fragment as a vaccine vector]. Xiaowu P; Fu WC; Guo YH; Zhang LS; Xie TP; Xinbin G Sheng Wu Gong Cheng Xue Bao; 2006 May; 22(3):492-8. PubMed ID: 16755933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]